Timely Intervention in T2DM: Focus on SGLT2-DPP-4 Inhibitor Combinations


Dr AG Unnikrishnan, Pune    06 June 2022

The sequential treatment approach is often compounded by substantial clinical inertia to timely treatment intensification. Substantial clinical inertia exists at each sequential intensification step.


At HbA1c 8.0% to 8.5%, HbA1c-lowering is slightly greater with DPP-4 inhibitors than with SGLT2 inhibitors as an add-on to metformin.


SGLT2 inhibitors are associated with larger HbA1c levels.


DPP-4 inhibitors moderate the risk of genitourinary tract infections associated with SGLT2 inhibitors.


In cases of HbA1c ≥8.0%, dual DPP-4 inhibitors-SGLT2 inhibitors add-on therapy to metformin should be considered to help more patients achieve glycemic targets.


Real-world evidence with empagliflozin and linagliptin FDC conducted across India involving 1232 T2D patients showed a significant reduction in HbA1c, FPG, PPG, weight and BP.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.